$ALEC
Alector, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023005111 Filed on February 28, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $16.55M $14.44M $133.6M
YoY Change -32.38% 3.19% -35.48%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.78M $15.39M $61.03M
YoY Change -5.0% -9.14% 10.89%
% of Gross Profit
Research & Development $51.89M $54.49M $210.4M
YoY Change -2.18% 3.23% 11.09%
% of Gross Profit
Depreciation & Amortization $1.360M $1.394M $5.714M
YoY Change -14.41% -12.55% -9.72%
% of Gross Profit
Operating Expenses $66.66M $69.88M $271.5M
YoY Change -2.82% 0.22% 11.05%
Operating Profit -$50.12M -$137.8M
YoY Change 13.58% 268.93%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $5.159M $3.731M $7.778M
YoY Change 1854.17% 2983.47% 654.41%
Pretax Income -$44.96M -$51.71M -$130.1M
YoY Change 2.5% -7.02% 257.99%
Income Tax $901.0K $0.00 $3.254M
% Of Pretax Income
Net Earnings -$45.86M -$52.43M -$133.3M
YoY Change 2.78% -5.72% 266.95%
Net Earnings / Revenue -277.1% -363.07% -99.77%
Basic Earnings Per Share -$0.55 -$1.62
Diluted Earnings Per Share -$0.55 -$0.62 -$1.62
COMMON SHARES
Basic Shares Outstanding 83.03M 82.70M 82.47M
Diluted Shares Outstanding 83.10M 82.47M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $669.3M $712.9M $712.9M
YoY Change -22.94% -3.05% -3.05%
Cash & Equivalents $195.6M $154.3M $154.3M
Short-Term Investments $473.8M $558.5M $558.5M
Other Short-Term Assets $11.97M $11.00M $11.00M
YoY Change 25.57% 55.52% 55.52%
Inventory
Prepaid Expenses
Receivables $4.699M $2.587M $2.587M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $686.0M $726.4M $726.4M
YoY Change -23.0% -3.1% -3.1%
LONG-TERM ASSETS
Property, Plant & Equipment $25.00M $25.52M $53.33M
YoY Change -4.69% -6.62% -7.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.804M $6.409M $7.881M
YoY Change 48.42% 14.98% 11.85%
Total Long-Term Assets $62.34M $61.21M $61.21M
YoY Change -1.87% -5.75% -5.75%
TOTAL ASSETS
Total Short-Term Assets $686.0M $726.4M $726.4M
Total Long-Term Assets $62.34M $61.21M $61.21M
Total Assets $748.3M $787.6M $787.6M
YoY Change -21.6% -3.32% -3.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.126M $4.189M $4.189M
YoY Change -53.7% -11.79% -11.79%
Accrued Expenses $18.58M $27.77M $41.39M
YoY Change -7.29% 1.13% -5.94%
Deferred Revenue $61.77M $48.23M
YoY Change -35.39% -46.88%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $99.30M $93.81M $93.81M
YoY Change -30.5% -32.78% -32.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $898.0K $759.0K $479.4M
YoY Change 468.35% 380.38% 28.05%
Total Long-Term Liabilities $898.0K $759.0K $479.4M
YoY Change 468.35% 380.38% 28.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $99.30M $93.81M $93.81M
Total Long-Term Liabilities $898.0K $759.0K $479.4M
Total Liabilities $565.3M $573.2M $573.2M
YoY Change -17.7% 11.53% 11.53%
SHAREHOLDERS EQUITY
Retained Earnings -$625.5M -$579.7M
YoY Change 27.4% 29.86%
Common Stock $8.000K $8.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $183.0M $214.4M $214.4M
YoY Change
Total Liabilities & Shareholders Equity $748.3M $787.6M $787.6M
YoY Change -21.6% -3.32% -3.32%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$45.86M -$52.43M -$133.3M
YoY Change 2.78% -5.72% 266.95%
Depreciation, Depletion And Amortization $1.360M $1.394M $5.714M
YoY Change -14.41% -12.55% -9.72%
Cash From Operating Activities -$48.55M -$48.93M -$20.33M
YoY Change -135.94% -0.69% -106.81%
INVESTING ACTIVITIES
Capital Expenditures $1.025M $766.0K $4.117M
YoY Change 48.12% -237.52% 26.79%
Acquisitions
YoY Change
Other Investing Activities $89.73M $19.15M -$154.9M
YoY Change -886.1% -113.1% 233.71%
Cash From Investing Activities $88.70M $18.38M -$159.0M
YoY Change -832.7% -112.53% 220.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.079M 636.0K 4.514M
YoY Change -56.54% -92.64% -85.1%
NET CHANGE
Cash From Operating Activities -48.55M -48.93M -20.33M
Cash From Investing Activities 88.70M 18.38M -159.0M
Cash From Financing Activities 1.079M 636.0K 4.514M
Net Change In Cash 41.23M -29.91M -174.8M
YoY Change -67.14% -84.04% -162.62%
FREE CASH FLOW
Cash From Operating Activities -$48.55M -$48.93M -$20.33M
Capital Expenditures $1.025M $766.0K $4.117M
Free Cash Flow -$49.57M -$49.69M -$24.45M
YoY Change -136.88% 2.02% -108.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://alector.com/20221231#CollaborationRevenueMember
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://alector.com/20221231#CollaborationRevenueMember
CY2020 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://alector.com/20221231#CollaborationRevenueMember
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001653087
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-38792
CY2022 dei Entity Registrant Name
EntityRegistrantName
Alector, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity File Number
EntityFileNumber
001-38792
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2933343
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
131 Oyster Point Blvd
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2022 dei City Area Code
CityAreaCode
415
CY2022 dei Local Phone Number
LocalPhoneNumber
231-5660
CY2022 dei Security12b Title
Security12bTitle
Common Stock
CY2022 dei Trading Symbol
TradingSymbol
ALEC
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
48231000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
90803000
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
false
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
627100000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83027910
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
San Mateo, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154323000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
329152000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
558528000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
406099000
CY2022Q4 alec Collaboration Receivable
CollaborationReceivable
2587000
CY2021Q4 alec Collaboration Receivable
CollaborationReceivable
7391000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10997000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7071000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
726435000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
749713000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25521000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27330000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27811000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
30569000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1472000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1472000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6409000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5574000
CY2022Q4 us-gaap Assets
Assets
787648000
CY2021Q4 us-gaap Assets
Assets
814658000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4189000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4749000
CY2022Q4 alec Accrued Clinical Supply Cost
AccruedClinicalSupplyCost
5559000
CY2021Q4 alec Accrued Clinical Supply Cost
AccruedClinicalSupplyCost
8748000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27771000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27460000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8059000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7795000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
93809000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
139555000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
443370000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
334415000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35268000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
39806000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
759000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
158000
CY2022Q4 us-gaap Liabilities
Liabilities
573206000
CY2021Q4 us-gaap Liabilities
Liabilities
513934000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82895718
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82895718
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81986192
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81986192
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
798696000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
748036000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4575000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-943000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-579687000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-446377000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
214442000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
300724000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
787648000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
814658000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
133617000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
207085000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21098000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
210418000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
189407000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
156869000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
61033000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
55038000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
59403000
CY2022 us-gaap Operating Expenses
OperatingExpenses
271451000
CY2021 us-gaap Operating Expenses
OperatingExpenses
244445000
CY2020 us-gaap Operating Expenses
OperatingExpenses
216272000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-137834000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-37360000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-195174000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7778000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1031000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4946000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3254000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-133310000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-130056000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-36329000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-190228000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-36329000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-190228000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-3632000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-1557000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
472000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-136942000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37886000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-189756000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.62
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.62
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.45
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.45
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82467587
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82467587
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
80416936
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80416936
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77758806
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77758806
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
194743000
CY2020 alec Issuance Costs Of Common Stock
IssuanceCostsOfCommonStock
1148000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
224511000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6331000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1179000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30522000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
472000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-190228000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
267530000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28530000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1765000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
40785000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1557000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-36329000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
300724000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3059000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1455000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
46146000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3632000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-133310000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
214442000
CY2022 us-gaap Profit Loss
ProfitLoss
-133310000
CY2021 us-gaap Profit Loss
ProfitLoss
-36329000
CY2020 us-gaap Profit Loss
ProfitLoss
-190228000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5714000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
6329000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5870000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
46146000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
40785000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
30522000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1163000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2099000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-584000
CY2022 alec Amortization Right Of Use Asset
AmortizationRightOfUseAsset
2758000
CY2021 alec Amortization Right Of Use Asset
AmortizationRightOfUseAsset
1986000
CY2020 alec Amortization Right Of Use Asset
AmortizationRightOfUseAsset
1395000
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2021 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2020 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
238000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-0
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-107000
CY2022 alec Increase Decrease In Collaboration Receivable
IncreaseDecreaseInCollaborationReceivable
-4804000
CY2021 alec Increase Decrease In Collaboration Receivable
IncreaseDecreaseInCollaborationReceivable
7391000
CY2020 alec Increase Decrease In Collaboration Receivable
IncreaseDecreaseInCollaborationReceivable
0
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3926000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1132000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3839000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
835000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2957000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2498000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-572000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1917000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2409000
CY2022 alec Increase Decrease In Accrued Liabilities And Accrued Clinical Supply Costs
IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts
-2655000
CY2021 alec Increase Decrease In Accrued Liabilities And Accrued Clinical Supply Costs
IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts
2391000
CY2020 alec Increase Decrease In Accrued Liabilities And Accrued Clinical Supply Costs
IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts
12232000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
66383000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
292915000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-21098000
CY2022 alec Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-4274000
CY2021 alec Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-4012000
CY2020 alec Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-2407000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
601000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-314000
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-21000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20329000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
298551000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-166734000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4117000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3247000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5032000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
556898000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
343402000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
506809000
CY2022 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2021 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
10696000
CY2020 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
402001000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
286290000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
406790000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-159014000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-49663000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-105051000
CY2022 alec Proceeds From Payments For Issuance Initial Public Offering
ProceedsFromPaymentsForIssuanceInitialPublicOffering
0
CY2021 alec Proceeds From Payments For Issuance Initial Public Offering
ProceedsFromPaymentsForIssuanceInitialPublicOffering
0
CY2020 alec Proceeds From Payments For Issuance Initial Public Offering
ProceedsFromPaymentsForIssuanceInitialPublicOffering
-224603000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3059000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28530000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6331000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1455000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1765000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1179000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4514000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30295000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
232113000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-174829000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
279183000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39672000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
330624000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51441000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91113000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155795000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
330624000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51441000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
493000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
705000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
428000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at financial institutions. Such deposits may, at times, exceed federally insured limits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154323000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
329152000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49969000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1472000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1472000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1472000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155795000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
330624000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51441000
CY2022 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2021 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2020 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
200000
CY2022Q4 alec Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
12321000
CY2021Q4 alec Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
13330000
CY2022 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1200000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
700000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
640800000
CY2022Q4 alec Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue
9600000
CY2021 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
10700000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
444900000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
307900000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
48133000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
44616000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22612000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17286000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25521000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27330000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12758000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11664000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1983000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1588000
CY2022Q4 alec Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
337000
CY2021Q4 alec Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
560000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
372000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
318000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27771000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27460000
CY2022 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease expires in 2029 with an option to renew for a period of ten years.
CY2022 alec Lease Expiration Year
LeaseExpirationYear
2029
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P10Y
CY2022 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
15700000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1500000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
6638000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
6204000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
5589000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
2785000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
3046000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
2255000
CY2022 alec Sublease Income And Reimbursement Of Variable Lease Cost1
SubleaseIncomeAndReimbursementOfVariableLeaseCost1
1872000
CY2021 alec Sublease Income And Reimbursement Of Variable Lease Cost1
SubleaseIncomeAndReimbursementOfVariableLeaseCost1
2141000
CY2020 alec Sublease Income And Reimbursement Of Variable Lease Cost1
SubleaseIncomeAndReimbursementOfVariableLeaseCost1
2288000
CY2022 us-gaap Lease Cost
LeaseCost
7551000
CY2021 us-gaap Lease Cost
LeaseCost
7109000
CY2020 us-gaap Lease Cost
LeaseCost
5556000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y2M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
8200000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
7900000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
6900000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8436000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8732000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
9037000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
9353000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
9681000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
11096000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
56335000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
13008000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
43327000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-27205000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
46146000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
40785000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30522000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
2209000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1045000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3254000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7627000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-39948000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-344000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-398000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-16570000
CY2022 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
20184000
CY2021 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
9389000
CY2020 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
8010000
CY2022 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
7733000
CY2021 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
2347000
CY2020 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
2003000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
4919000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-2368000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
353000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
38421000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
16800000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
62280000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-86000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-161000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-108000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3254000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20963000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
63868000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
806000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1811000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
26319000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
19614000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
13351000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
9656000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
67673000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
27849000
CY2022Q4 alec Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
10055000
CY2021Q4 alec Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
11296000
CY2022Q4 alec Deferred Tax Assets Tax Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts
35150000
CY2021Q4 alec Deferred Tax Assets Tax Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts
0
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1608000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
694000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
175925000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
134788000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
164316000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
122046000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
11609000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
12742000
CY2022Q4 alec Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
5155000
CY2021Q4 alec Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
5488000
CY2022Q4 alec Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
6454000
CY2021Q4 alec Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
7254000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
11609000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
12742000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
42300000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4592000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
59000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2406000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6939000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
8199000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15138000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
8200000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2400000
CY2022 alec Reversal Reserves On Uncertain Tax Provisions
ReversalReservesOnUncertainTaxProvisions
0
CY2021 alec Reversal Reserves On Uncertain Tax Provisions
ReversalReservesOnUncertainTaxProvisions
100000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16925023
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13088350
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12928100

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-005111-index-headers.html Edgar Link pending
0000950170-23-005111-index.html Edgar Link pending
0000950170-23-005111.txt Edgar Link pending
0000950170-23-005111-xbrl.zip Edgar Link pending
alec-20221231.htm Edgar Link pending
alec-20221231.xsd Edgar Link pending
alec-ex10_11.htm Edgar Link pending
alec-ex10_18.htm Edgar Link pending
alec-ex23_1.htm Edgar Link pending
alec-ex31_1.htm Edgar Link pending
alec-ex31_2.htm Edgar Link pending
alec-ex32_1.htm Edgar Link pending
alec-ex32_2.htm Edgar Link pending
alec-20221231_cal.xml Edgar Link unprocessable
alec-20221231_def.xml Edgar Link unprocessable
alec-20221231_lab.xml Edgar Link unprocessable
alec-20221231_pre.xml Edgar Link unprocessable
alec-20221231_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
img42979713_0.gif Edgar Link pending
img42979713_1.gif Edgar Link pending
img42979713_10.jpg Edgar Link pending
img42979713_11.gif Edgar Link pending
img42979713_12.gif Edgar Link pending
img42979713_13.jpg Edgar Link pending
img42979713_14.gif Edgar Link pending
img42979713_15.gif Edgar Link pending
img42979713_16.gif Edgar Link pending
img42979713_17.gif Edgar Link pending
img42979713_18.gif Edgar Link pending
img42979713_19.jpg Edgar Link pending
img42979713_2.gif Edgar Link pending
img42979713_20.jpg Edgar Link pending
img42979713_21.gif Edgar Link pending
img42979713_3.gif Edgar Link pending
img42979713_4.gif Edgar Link pending
img42979713_5.gif Edgar Link pending
img42979713_6.gif Edgar Link pending
img42979713_7.gif Edgar Link pending
img42979713_8.gif Edgar Link pending
img42979713_9.gif Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending